Eramol's Sterile Facility Targets >1% Material Loss for Biotech Clients

About this episode

Peter Mollison and David Cox discuss Eramol's new sterile injectable facility designed to minimize material loss for biotech clients.

"Every milliliter lost translates to delayed timelines and increased costs." For early-phase biotech companies working with limited API batches, this is the central challenge of sterile injectable manufacturing. Peter Mollison, CEO and co-founder of Eramol, a UK-based pharmaceutical CMO, has built an entire facility around solving it. Peter Mollison and David Cox, Site Director at Eramol, joined the PharmaSource podcast to discuss the company's new purpose-built sterile injectable facility opening in Q2 2026 in Sittingbourne, Kent. The 11,000-square-foot site features a 2,000-square-foot GMP Grade A/C/D clean room suite engineered to achieve less than 1% material losses, well below the industry standard of approximately 10%. In this episode, Peter and David explain the engineering decisions behind the low-waste design, how the facility's end-to-end capabilities simplify outsourcing for biotech, academia, and research clients, and what it takes to build a sterile manufacturing site that meets 2023 EU GMP Annex One standards. Read more .

People in this episode

Guests: Peter Mollison, David Cox

Topics covered

• sterile injectable manufacturing
• biotech challenges
• material loss reduction
• GMP standards
• pharmaceutical CMO

Keywords

• sterile facility
• biotech
• material loss
• injectable manufacturing
• GMP clean room

Mentioned in this episode

Organizations: Eramol, EU GMP Annex One

Places: Sittingbourne, Kent

More episodes of PharmaSource Podcast

• How Sanofi Navigates Regulatory CMC Across Global Markets: Insights from Manda Pasarkar · June 11, 2026 · 31 min
• The Politics Behind the Pipeline: How MFN Pricing and Tariffs Are Reshaping Pharma's Global Strategy · June 8, 2026 · 18 min
• How to Build a Resilient Global Vaccine Supply Chain: From Crisis to Capability · June 4, 2026 · 46 min
• How Lonza Is Outgrowing the CDMO Market with Bioconjugation, AI, and Regionalization · May 31, 2026 · 29 min
• The Strategic Partnership Gap: Why CDMOs Are Meeting Pharma's Expectations Less Than Half the Time with Simon-Kucher · May 27, 2026 · 26 min
• Creative Financing Strategies for Biotech's Bear Market, Beyond the VC Round · May 25, 2026 · 29 min